Care to add some details? It's certainly a possibility, and I will not be adding any more to my position because of this possibility, but don't you think there's at least some chance that LLY would want to take a chance on a potentially improved Humalog (again, I'm assuming BIOD is developing a potentially better Humalog and hopes to ink a deal with LLY) with Humalog set to go generic in the next few years? And, if this does turn out to be the case, what do you see as the upside for a company with a market cap of ~$30M and cash to see them through to March 2013?
Market Data 
Markets 
AI
